Abstract
Recently, a letter to the Editor entitled ‘Testing the Effectiveness of MyPROSLE in Classifying Patients with Lupus Nephritis’ has been submitted by Leventhal et al. to Briefings in Bioinformatics. In this letter, the authors test MyPROSLE, a web application we recently introduced [ 1], to characterizelupus patients from the molecular point of view. Leventhal et al. tested the application with independent datasets reporting that the software ‘did not perform sufficiently well to consider replacement of the standard kidney biopsy as a diagnostic procedure’. In this letter, we address in detail all the concerns described by Leventhal et al.
Funding Information
  • FEDER and the Innovative Medicines Initiative 2 Joint Undertaking (PID2020-119032RB-I00, MCIN/AEI/10.13039/501100011033, 831434)
  • FEDER/Junta de Andalucía-Consejer’a de Transformación Económica, Industria, Conocimiento y Universidades (P20_00335, B-CTS-40-UGR20)
  • Consejería de Transformación Económica, Industria, Conocimiento y Universidades